Company intelligence / Profile preview

Phoenix Technologies

San Antonio, Texas, United States

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Oleandrin and oleander extracts show promising in vitro and early clinical evidence for antiviral (including COVID-19), anticancer, neuroprotective, and anti-inflammatory activities, but FDA approval for oleandrin as a dietary supplement was denied.

Therapeutic areas: OncologyInfectious DiseasesDermatologyNeurology
Modalities: Natural productSmall moleculeBotanical extract (Oleandrin)
Industry: Biotech

Partnerships

Collaborations with US Army, Southern Methodist University, Duke University, University of Texas MD Anderson Cancer Center, Johns Hopkins Medical Center, CDC, World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, NIS Labs

Beyond the preview

Go deeper on Phoenix Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoenix Technologies.

Explore the full profile